Velpanat Tablet

Velpanat tablets may cause certain side effects. If side effects occur after administration or last longer than usual, contact your healthcare professional.​

• Hepatitis B reactivation
  
• Severe allergic reactions
  
• Headache
  
• Dizziness
  
• Fatigue / Weakness
  
• Nausea
• Vomiting
• Insomnia (difficulty sleeping)
  
• Diarrhea
  
• Constipation
  
• Itching (pruritus)
  
• Decreased appetite
  
• Muscle or joint pain
  
• Rash
  
• Fever
  
• Anemia (low red blood cells)
  
• Neutropenia (low white blood cells)
  
• Breathing problems / Difficulty breathing
  
• Cough
  
• Bone pain
• Slow heart rate

​Take Velpanat tablets exactly as your healthcare provider tells you. Do not crush, chew, or break the tablet. Swallow as a whole. ​Seek emergency medical support in case of overdose.

• The Velapanat tablet is a combination of two antiviral medicines, such as Sofosbuvir and Velpatasvir.
•  It works by blocking the replication of the virus to reduce its levels in the body. 
• By suppressing viral replication, it helps to slow down the progression of liver damage and clear up the infection.
  

Please consult your healthcare provider in case you miss a dose. Do not double the dose to cover up, unless your doctor sugeest you.

• Tests for hepatitis B before starting treatment to reduce the risk of HBV reactivation.

• Velpanat Tablet must not be combined with amiodarone, risking fatal bradycardia.

• May cause fatigue, dizziness, or blurred vision; avoid driving or tasks needing focus until you know how it affects you.

• Headaches are common; drink plenty of water and use a suitable painkiller; inform your doctor if they are persistent.

• Liver function and viral load should be monitored regularly during treatment.

At our pharmacy, your health is our top priority. All of our medicines are safe, effective, and approved by leading health authorities. We partner exclusively with reliable and reputable manufacturers, ensuring the highest quality standards in every product we deliver.

Enjoy the convenience of fast home delivery, secure packaging, and affordable prices—plus special discounts on bulk orders. We’re proud to offer international shipping to a wide range of countries across Asia, Europe, Africa, the Americas, and beyond, making trusted healthcare accessible no matter where you are.

Whether you're a patient or a healthcare provider, you can order with confidence and compassion. Our goal is to ensure that quality healthcare reaches everyone, everywhere.


We currently ship to:

Barbados, Haiti, Trinidad and Tobago, Mexico, Bahamas, Ecuador, Peru, Chile, Brazil, Colombia, Philippines, U.K., USA, Kuwait, Saudi Arabia, UAE, Oman, Qatar, Japan, Ireland, Russia, China, France, Australia, Lithuania, Nigeria, Romania, Algeria, Canada, Singapore, Thailand, Hong Kong, Bahrain, Jordan, Indonesia, Hungary, Moldova, Bulgaria, Azerbaijan, Congo, Ethiopia, Lebanon, Morocco, Mozambique, South Korea, Sri Lanka, Belarus, Mongolia, Malaysia, Vietnam, Tunisia, Zambia, and Israel.
Experience the quality everyone’s talking about – order today!

• Feld, J. J., Jacobson, I. M., Hézode, C., Asselah, T., Ruane, P., Gruener, N., … Chan, H. L. Y. (2015). Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. New England Journal of Medicine, 373(27), 2599–2607. https://doi.org/10.1056/NEJMoa1512610.
  
• Feld et al. (2015). Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. New England Journal of Medicine, 373(27), 2608–2617. https://doi.org/10.1056/NEJMoa1512612.
  
• Chandrashekhar et al. (2019). Sofosbuvir–velpatasvir single-tablet regimen administered for 12 weeks in a phase 3 study with minimal monitoring in India. Hepatology International. https://doi.org/10.1007/s12072‑019‑09927‑6 Chang Gung Medical Foundation (2021). Effectiveness of sofosbuvir/velpatasvir in patients with advanced fibrosis or cirrhosis: a population-based study in Taiwan. Infectious Diseases and Therapy.
  
• Gaur, N. et al. (2019). Sofosbuvir–velpatasvir fixed-dose combination for treatment of chronic hepatitis C infection in patients with end-stage renal disease and kidney transplantation. Journal of Clinical and Experimental Hepatology, 10(3), 189–193.
  
• Shah, V. et al. (2023). Sofosbuvir/velpatasvir/voxilaprevir for hepatitis C virus retreatment in difficult-to-treat patients: A real-life observational study from India. Journal of Clinical and Experimental Hepatology.